^
    1d
    CAREMM-011: CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    2d
    iFIT: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (clinicaltrials.gov)
    P3, N=1226, Not yet recruiting, University of Leeds
    New P3 trial
    |
    IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    4d
    Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. (PubMed, Kidney Med)
    Daratumumab-based induction therapy resulted in a partial renal response (urinary protein-creatinine ratio of 0.7 g/g)...To our knowledge, this case represents only the second reported case of HTRA1-MN occurring in the setting of monoclonal gammopathy, the first in multiple myeloma, and a rare example of a nonmonotypic MN in this context. Temporal proximity and partial response to anti-plasma cell therapy suggest a possible paraneoplastic relationship, although a causal relationship remains unproven.
    Journal
    |
    HTRA1 (HtrA Serine Peptidase 1)
    |
    Darzalex (daratumumab)
    7d
    ALLG MM21: Daratumumab-lenalidomide-dexamethasone (DRd) salvage for newly diagnosed Multiple Myeloma patients who fail bortezomib induction therapy (ACTRN12618001490268)
    P2, N=50, Completed, Australiasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    8d
    A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, CASI pharmaceuticals, Inc.
    New P1/2 trial
    |
    IL6 (Interleukin 6)
    8d
    Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype. (PubMed, Cancer Immunol Res)
    Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM...Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell-redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PD-L1 expression
    |
    Elrexfio (elranatamab-bcmm) • SAR442257 • Abecma (idecabtagene vicleucel)
    8d
    EMN2868284528MMY3005: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (2023-507632-20-00)
    P2/3, N=440, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel)
    9d
    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    10d
    AQUILA: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P3, N=390, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    11d
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    13d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    14d
    SCILLA: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, Odense University Hospital | Trial completion date: Jun 2027 --> Jan 2028 | Initiation date: Jan 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)